Top

Osteoporosis International

Published in:

01-12-2018 | Original Article

Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials

Authors: Y. S. Zhang, W. Y. Weng, B. C. Xie, Y. Meng, Y. H. Hao, Y. M. Liang, Z. K. Zhou

Published in: Osteoporosis International | Issue 12/2018

Abstract

Summary

Our network meta-analysis analyzed the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on fracture risk. By combining data from randomized controlled trials, we found that GLP-1 RAs were associated with a decreased bone fracture risk, and exenatide is the best option agent with regard to the risk of fracture. This study is registered with PROSPERO (CRD42018094433).

Introduction

Data on the effects of GLP-1 RAs on fracture risk are conflicted. This study aimed to analyze the available evidence on the effects of GLP-1 RAs on fracture risk in type 2 diabetes mellitus patients.

Methods

Electronic databases were searched for relevant published articles, and unpublished studies presented at ClinicalTrials.gov were searched for relevant clinical data. All analyses were performed with STATA 12.0 and R software (Version 3.4.4). We estimated the risk ratio (RR) and 95% confidence interval (CI) by combining RRs for fracture effects of included trials.

Results

There were 54 eligible random control trials (RCTs) with 49,602 participants, including 28,353 patients treated with GLP-1 RAs. Relative to placebo, exenatide (RR, 0.17; 95% CI 0.03–0.67) was associated with lowest risk of fracture among other GLP-1 RAs. Exenatide had the highest probability to be the safest option with regard to the risk of fracture (0.07 ‰), followed by dulaglutide (1.04%), liraglutide (1.39%), albiglutide (5.61%), lixisenatide (8.07%), and semaglutide (18.72%). A statistically significant inconsistency was observed in some comparisons.

Conclusion

The Bayesian network meta-analysis suggests that GLP-1 RAs were associated with a decreased bone fracture risk compared to users of placebo or other anti-hyperglycemic drugs in type 2 diabetes mellitus patients, and exenatide is the best option agent with regard to the risk of fracture.

Available only for authorised users

Unnikrishnan R, Mohan V (2016) Diabetes in the tropics: prevalent, increasing and a major public health problem. Trans R Soc Trop Med Hyg 110:263–264CrossRef

Drucker DJ (2018) Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 27:740–756CrossRef

Gallwitz B (2015) GLP-1 receptor agonists in type 2 diabetes and beyond - new insights 2015. Eur Endocrinol 11:21–25CrossRef

Mabilleau G, Gobron B, Bouvard B, Chappard D (2018) Incretin-based therapy for the treatment of bone fragility in diabetes mellitus. Peptides 100:108–113CrossRef

Goldshtein I, Nguyen AM, DePapp AE, Ish-Shalom S, Chandler JM, Chodick G, Shalev V (2018) Epidemiology and correlates of osteoporotic fractures among type 2 diabetic patients. Arch Osteoporos 13:15CrossRef

Epstein S, Defeudis G, Manfrini S, Napoli N, Pozzilli P (2016) Diabetes and disordered bone metabolism (diabetic osteodystrophy): time for recognition. Osteoporos Int 27:1931–1951CrossRef

de Liefde II, van der Klift M, de Laet CE, van Daele PL, Hofman A, Pols HA (2005) Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int 16:1713–1720CrossRef

Schwartz AV, Vittinghoff E, Bauer DC, Hillier TA, Strotmeyer ES, Ensrud KE, Donaldson MG, Cauley JA, Harris TB, Koster A, Womack CR, Palermo L, Black DM (2011) Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA 305:2184–2192CrossRef

Faltinsen EG, Storebo OJ, Jakobsen JC, Boesen K, Lange T, Gluud C (2018) Network meta-analysis: the highest level of medical evidence? BMJ Evid Based Med 23:56–59CrossRef

10.

Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928CrossRef

11.

Dias S, Sutton AJ, Ades AE, Welton NJ (2013) Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Mak 33:607–617CrossRef

12.

Mills EJ, Thorlund K, Ioannidis JP (2013) Demystifying trial networks and network meta-analysis. BMJ 346:f2914CrossRef

13.

Mawdsley D, Bennetts M, Dias S, Boucher M, Welton NJ (2016) Model-based network meta-analysis: a framework for evidence synthesis of clinical trial data. CPT Pharmacometrics Syst Pharmacol 5:393–401CrossRef

14.

Dias S, Welton NJ, Caldwell DM, Ades AE (2010) Checking consistency in mixed treatment comparison meta-analysis. Stat Med 29:932–944CrossRef

15.

Cooper NJ, Sutton AJ, Lu G, Khunti K (2006) Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation. Arch Intern Med 166:1269–1275CrossRef

16.

van Valkenhoef G, Dias S, Ades AE, Welton NJ (2016) Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis. Res Synth Methods 7:80–93CrossRef

17.

Dias S, Sutton AJ, Welton NJ, Ades AE (2013) Evidence synthesis for decision making 3: heterogeneity--subgroups, meta-regression, bias, and bias-adjustment. Med Decis Mak 33:618–640CrossRef

18.

Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G (2013) Graphical tools for network meta-analysis in STATA. PLoS One 8:e76654CrossRef

19.

Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008–2012CrossRef

20.

Mabilleau G, Mieczkowska A, Chappard D (2014) Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials. J Diabetes 6:260–266CrossRef

21.

Su B, Sheng H, Zhang M, Bu L, Yang P, Li L, Li F, Sheng C, Han Y, Qu S, Wang J (2015) Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials. Endocrine 48:107–115CrossRef

22.

Zeng I, Lumley T (2018) Review of statistical learning methods in integrated omics studies (an integrated information science). Bioinf Biol Insights 12:1216874372CrossRef

23.

Gunhan BK, Friede T, Held L (2017) A design-by-treatment interaction model for network meta-analysis and meta-regression with integrated nested Laplace approximations. Res Synth Methods 9:179–194CrossRef

Title: Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials
Authors: Y. S. Zhang
W. Y. Weng
B. C. Xie
Y. Meng
Y. H. Hao
Y. M. Liang
Z. K. Zhou
Publication date: 01-12-2018
Publisher: Springer London
Published in: Osteoporosis International / Issue 12/2018
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-018-4649-8

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials

Abstract

Summary

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2018

Contribution of bone turnover markers to the variation in bone mineral density: a study in Vietnamese men and women

Osteogenesis imperfecta and the teeth, eyes, and ears—a study of non-skeletal phenotypes in adults

Bone fragility after spinal cord injury: reductions in stiffness and bone mineral at the distal femur and proximal tibia as a function of time

Diagnosis and management of bone fragility in diabetes: an emerging challenge

Notch in skeletal physiology and disease

Bone mineral density in osteoporotic patients with pyogenic vertebral osteomyelitis: effect of early versus late treatment for osteoporosis